Navigation Links
Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
Date:4/13/2009

s in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements regarding the parties' ability to consummate the transactions, relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease, the potential for milestone, royalty and other payments under the collaboration with Prometheus, and the potential development of two new microRNA-based gastroenterology tests, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead to commercially accepted products or services; Rosetta's ability to obtain, maintain and protect its intellectual property; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's need and ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history;
'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
3. Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests
4. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
5. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
6. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
7. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
8. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
9. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
10. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
11. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Genomic Health, Inc. (Nasdaq: ... host a conference call and webcast on Thursday, August 7 ... 2014 financial results.  The call and webcast will follow the ... Conference Call Details To access the live conference ... phone, please dial (877) 303-7208 from the United ...
(Date:7/31/2014)... -- Celsion Corporation (NASDAQ: CLSN ) announced today ... discuss its second quarter 2014 financial results at 11:00 ... in the call, interested parties may dial 1-800-533-7954 (Toll-Free/ ... ask for the Celsion Corporation Second Quarter 2014 Conference ... the call is scheduled to begin. The call will ...
(Date:7/31/2014)... , 31. Juli 2014 Marken hat ... Miami bekanntgegeben, um die wachsenden logistischen ... Lateinamerika zu erfüllen. Die neu ausgebaute Einrichtung wird ... und für die Zusammenlegung von Sendungen in und ... Lagerkapazität bereitstellen.   Logo - ...
Breaking Medicine Technology:Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4Celsion Corporation to Hold Second Quarter 2014 Financial Results 2Marken erweitert regionales Logistikzentrum in Miami 2
... Aug. 6 MicroDose Technologies,Inc., a privately ... announces top line results from a glucose ... MicroDose, through its joint venture with Vectura,Group ... efficient, rapid acting,insulin inhaler, based upon MicroDose,s ...
... today reported financial results for the quarter ended June ... $3.1 million, compared with,revenues of $7.3 million for the ... quarter of 2007 was $8.2 million, or $0.21 per ... $0.11 per share, for the second quarter,of 2006. The ...
Cached Medicine Technology:MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study 2MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study 3MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study 4Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 2Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 3Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 4Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 5Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 6
(Date:7/31/2014)... July 31, 2014 Insight Accelerator Labs ... Series A round of investment for $4.6 million to ... for collecting vital signs. The company joined Insight ... to fruition with the help of Insight development teams. ... reason for launching the Accelerator,” says Steve McPhilliamy, Executive ...
(Date:7/31/2014)... The VitalSleep anti snoring device is a mandibular advancement splint ... snorers airway to quiet snoring. , Dawn M. of Utah ... her husband by allowing them to share the same bedroom again. ... about 15 years ago and I remember nights when it was ... had to head downstairs for any relief. As the years have ...
(Date:7/31/2014)... rising steadily in the U.S in recent years. According ... the number of individuals reporting past year heroin use ... evidence suggests the increase may be linked to prescription ... PO use to heroin use, with POs providing the ... This drug-use trajectory appears to have become increasingly ...
(Date:7/31/2014)... CO (PRWEB) July 31, 2014 Ticket ... vs. Bolivia tickets at Dick’s Sporting Goods Park in ... years, the Mexican national soccer team has found a second ... and failures during their time playing international friendly games and ... Bolivia at Dick’s Sporting Goods Park in Commerce City, Colorado. ...
(Date:7/31/2014)... from Carnegie Mellon University have developed a novel ... reminiscent of fibers found in living cells. The ... materials for drug delivery and tissue engineering applications. ... issue of Angewandte Chemie International Edition . ... linkers to protein molecules, we can form completely ...
Breaking Medicine News(10 mins):Health News:Insight Accelerator Labs Advances Member Toward Commercialization 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 3Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 2Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 3Health News:Carnegie Mellon chemists create nanofibers using unprecedented new method 2
... of 70 suffers from gait disturbance. To prevent falls, ... of Deutsches rzteblatt International, Klaus Jahn and ... Arztebl Int 107[17]: 306-16)., Gait disturbance is defined as ... slowing of old age. It often has multiple causes; ...
... Research also shows students are less aggressive and disruptive ... involvement in a child,s elementary school experience leads to ... new research suggests. , "The study shows that parents ... elementary school," the University of Pittsburgh research team said ...
... researchers at the University of Helsinki have found a mechanism ... of the brain for the information processing required later in ... science magazine The Journal of Neuroscience. The ... quite loosely interconnected. In the middle of chaos, they are ...
... hours, odds for good recovery decline sharply and risk of ... -- Patients who get the clot-busting drug alteplase (tPA) within ... who are given the drug later, Scottish doctors report. , ... better than later, but this study shows for the first ...
... ... and creates undue anxiety for women. , ... (PRWEB) May 14, 2010 -- A guide to BRCA1 and ... to equip physicians and other healthcare professionals who are not trained in genetics with ...
... ... fresh water aquatic fish habitats. With composition similar to natural rock formations, MarinePure ... , ... (PRWEB) May 14, 2010 -- CerMedia announced today at Interzoo 2010 in Nürnberg, Germany, ...
Cached Medicine News:Health News:New information on the development of the brain 2Health News:Early Treatment With Clot-Busting Drug Best After Stroke 2Health News:Early Treatment With Clot-Busting Drug Best After Stroke 3Health News:Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing 2Health News:Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing 3Health News:CerMedia Releases MarinePure High Surface Area Media for Aquatic Biofiltration 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: